The IMOR Foundation,Medical Institute for Radiation Oncology has been awarded the Judith Stitt Award considered the highest honour in the world, by the (American brachytherapy Society) for its outstanding contribution to the conservative treatment of prostate cancer and the continuous improvementof the quality of life of patients. . The award was presented in Toronto to Professor Benjamín Guix, who gave a conference entitled Treatment of intermediate or high risk prostate cancer using intensity modulated radiation therapy (IMRT) and brachytherapy.
Doctor Benjamín Guix director of the IMOR Foundation, speaks to Vanguardia Salud about the advantages of intraoperative radiotherapy for breast cancer.
Early diagnosis improves prognosis and treatment is more effective and with fewer side effects.
A Spanish study published in the International Journal of Radiation Oncology-Biology-Physics which included the participation of the IMOR Foundation, Medical Institute for RadiationOncology in Barcelona, concluded that patients with low-risk localised prostate cancer maintain a better quality of life when treated with brachytherapy than with surgery or radiotherapy alone, and that brachytherapy combined with IMRT offers a better quality of life to patients with localised intermediate or high-risk prostate cancer.
In an interview in Periódico Universal, Doctor Benjamín Guix, director of the IMOR Foundation, Medical Institute for Radiation Oncology in Barcelona, explained the advances in radiation therapy and brachytherapy that now make it possible to cure the vast majority of patients with tumours.
Elderly patients with prostate cancer who are treated actively show much better progress than those who adopt expectant behaviour or not very efficient treatments. The article describes how patients over 75 treated actively (with brachytherapy or radiation therapy) for prostate cancer instead of follow-up of the progression of the disease, have a risk of dying from any cause of only a third that of patients who receive no treatment.